Hirakata, Japan

Ikuko Miyagi

This inventor holds 2 USPTO granted patents. Top assignee: The Green Cross Corporation. Active years: 1995-1996.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Location History:

  • Hirakata, JP (1995)
  • Osaka, JP (1996)

Company Filing History:


Years Active: 1995-1996

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ikuko Miyagi: Innovator in Chelating Agents

Introduction

Ikuko Miyagi is a prominent inventor based in Hirakata, Japan. She has made significant contributions to the field of chemistry, particularly in the development of chelating agents. Her innovative work has led to the creation of compounds that are essential in medical imaging.

Latest Patents

Ikuko Miyagi holds 2 patents related to her research. Her latest patents focus on a chelating agent and a complex compound that includes a metallic atom. These compounds are designed to serve as diagnostic agents, exhibiting superior characteristics as contrast mediums for image diagnosis. The detailed formula of her compound includes various components that enhance its effectiveness in medical applications.

Career Highlights

Miyagi's career is marked by her dedication to advancing chemical research. She has worked extensively on developing compounds that improve diagnostic imaging techniques. Her contributions have been recognized within the scientific community, establishing her as a leading figure in her field.

Collaborations

Throughout her career, Ikuko Miyagi has collaborated with notable colleagues, including Fumio Mori and Tadashi Okano. These partnerships have fostered innovation and have been instrumental in her research endeavors.

Conclusion

Ikuko Miyagi's work in the field of chelating agents has made a significant impact on medical diagnostics. Her innovative compounds continue to enhance imaging techniques, showcasing her dedication to advancing science and technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…